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A B S T R A C T
Nitric oxide (NO) has dicotomic inﬂuence on modulating host-parasite interplay, synchronizing physiological
orchestrations and diagnostic potential; instigated us to investigate the plausible association and genetic reg-
ulation among NO level, components of oxidative stress, iNOS polymorphisms and risk of malaria. Here, we
experimentally elucidate that iNOS promoter polymorphisms are associated with risk of malaria; employing
mutation speciﬁc genotyping, functional interplay using western blot and RT-PCR, quantitative estimation of
NO, total antioxidant content (TAC) and reactive oxygen species (ROS).
Genotyping revealed signiﬁcantly associated risk of P. vivax (adjusted OR = 1.92 and 1.72) and P. falciparum
(adjusted OR = 1.68 and 1.75) infection with SNP at iNOS-954G/C and iNOS-1173C/T positions, respectively;
though vivax showed higher risk of infection. Intriguingly, mutation and infection speciﬁc diﬀerential upregu-
lation of iNOS expression/NO level was observed and found to be signiﬁcantly associated with mutant geno-
types. Moreover, P. vivax showed pronounced iNOS protein (2.4 fold) and mRNA (2.5 fold) expression relative to
healthy subjects. Furthermore, TAC and ROS were signiﬁcantly decreased in infection; and diﬀerentially de-
creased in mutant genotypes.
Our ﬁndings endorse polymorphic regulation of iNOS expression, altered oxidant-antioxidant components
and evidences of risk association as the hallmark of malaria pathogenesis. iNOS/NO may serve as potential
diagnostic marker in assessing clinical malaria.
1. Introduction
Malaria is a serious public health concern across the globe with a
preferential dominance in tropical regions, including India. Despite of
worldwide initiatives and eﬀorts for prevention, prompt diagnosis,
curative measures and possible eradication strategies; the global burden
of malaria as a life threatening disease continues to worsen globally
with a deplorable impact on human health and corresponding im-
pediment to economic development. According to the recent estimate of
WHO, 214 million cases of malaria occurred globally in 2015 and
43800 deaths; about 88% of the cases were from African region and
10% were from South-East Asia Region (SEAR) countries (WHO, World
malaria report- 2015). India contributes to 70% of malaria cases and 32
per cent of malaria deaths among SEAR countries. Approximately 569
million people reside in high transmission areas in India, i.e. deﬁned as
more than one case per 1000 population (WHO-2013 [1]). Falciparum
malaria accounts for approximately 247 million cases and one million
deaths annually, particularly in sub-Saharan Africa [2] while outside
the African continents, Plasmodium vivax is responsible for more than
50% of all malaria cases [3]. Outside of Africa, Plasmodium falciparum
and P. vivax almost invariably coexist and are often equally prevalent
[4], yet the public health importance of P. vivax is frequently over-
looked [5]. Plasmodium vivax threatens almost 40% of the world's po-
pulation, causing an estimated 72–390 million clinical infections each
year [3,6].
Malaria is not uniformly distributed in India; ranging from sectarian
low to high transmission zones with a prevalence of perennial trans-
mission in malaria endemic regions. However, transmission intensities
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and incidence rates diﬀer by seasonal changes, punctuated by a risk of
epidemic every three to ﬁve years period. Higher and stable transmis-
sion were observed in geographically conducive i.e. forested and hilly
areas with a sizable tribal settlements in the state of Andhra Pradesh,
Jharkhand, Gujarat, Madhya Pradesh, Chhattisgarh, Orissa and
Rajasthan. Jharkhand is an understudied and tribal prevalent region
with perennial malaria transmission zone where malaria is rampant and
causing 20 × 103 annual malaria deaths, second to Orissa in India as
per the latest observation published by Dhingra et al. [7], which reﬂects
the importance of the area and the necessity of undertaking extensive
investigation in terms of malarial pathology is concerned. The mor-
bidity in Jharkhand ranges from 1.5 to 2.3 Lakh cases annually,
whereas, the mortality ranges from 16 to 35 cases annually over the last
three years as per the Directorate of National Vector Born Disease
Control Programme, India and Ministry of Health and Family Welfare,
Govt. of India.
In view of the augmented pathology, poorly elucidated disease
progression and underlying mechanisms, intriguing clinical variability,
selective drug pressure and their discriminate use resulting into varied
level of resistance, long awaited eﬃcient therapeutic interventions and
distant insights for eﬀective and protective vaccine; all accumulated
factors continue to perplex the situation for parasitologist over the past
century but the reason and mechanisms of which remain enigmatic.
This very situation demands exploration of alternative domains such as
descriptive genetic epidemiology; which may open new vistas in un-
derstanding the role of genetic factors involved in resistance/suscept-
ibility to diseases. Genetic factors play a key role in disease diagnosis,
susceptibility and progression, and have translational signiﬁcance for
developing strategies to control the disease. Malaria parasites, as one of
the oldest known parasite infecting humans, have had a long evolu-
tionary host-parasite association. Among the various associating fac-
tors, identifying polymorphic variability in the parasite and the host
candidate genes inﬂuencing disease risk and severity to plasmodium
infection, is of paramount signiﬁcance. Considering the magnitude of
public health concern, we decided to select a gene from the bigger
partner of association i.e. host gene and among them, nitric oxide (NO)
was chosen as a potential candidate gene in view of its documented role
in host defense machinery against infectious invasion by a variety of
organisms [8,9]. A number of studies, both in-vitro and in-vivo espe-
cially from laboratory models of various protozoan infections including
plasmodium, implicated nitric oxide as an integral component of the
host armament against invading parasites and infectious agents. The
underlying mechanism by which nitric oxide mediates defensive or-
chestration is either through direct parasite killing or by limiting
parasite growth [10–12], though the working eﬃciency depends upon
the various factors like site of action, timing and amount of its pro-
duction and biological milieu in which it is released [10]. However,
precise clinical relevance and role of nitric oxide in malarial etiology is
dicotomic, as some investigators have associated NO with severity of
malaria, particularly cerebral malaria [13–17], whereas, others opine
that nitric oxide has a protective role [18–23]. Upon the triggering of
immunologic or inﬂammatory stimulus, NO is constitutively produced
from monocytes/macrophages by the enzymatic action of nitric oxide
synthase. The enzyme catalyzing the production of nitric oxide is dif-
ferentiated on the basis of their origin i.e. endothelial (eNOS or NOS3),
neuronal (nNOS or NOS1) and the most abundant in concentration, the
inducible nitric oxide synthase (iNOS or NOS2) [24]. The most sus-
tained and highest production of nitric oxide is induced by iNOS [25]
and contributes in intrahepatic killing of parasites in response to IFN-γ,
TNF-α, IL-1β and IL-6 secreted by antigen-speciﬁc T cells and NK cells
[26,27]. Production of nitric oxide is regulated through the enzymatic
induction of NOS gene and it has been reported that NOS gene as host
genetic factor do contribute to the variation in the frequency and in-
tensity of clinical episode of malaria [28,29] and other infection [30].
Several NOS2 promoter polymorphisms have been studied in context of
malaria pathology and severity. However, single nucleotide
polymorphisms (SNPs) in the promoter region of the encoding gene at
−954G/C and −1173C/T have been shown to increase NO synthesis
[31,32]. Initially these polymorphism were observed to be associated
with African populations [33] but recently similar observations were
reported in studies extended to other malaria-endemic regions, such as
Tanzania [34], Americans of African origin [34], Southeast Asia
[35,36], white Americans [34] and Germans [20]. Additionally, inter-
esting but ambiguous reports regarding the role of NO in malaria
emerged from two recent studies; Kun et al. [20] demonstrated an as-
sociation between polymorphism in the promoter region of the iNOS
gene and protection from severe malaria in a Gabonese population,
whereas, observations made by Burgner et al. [13] on Gambian popu-
lation were somewhat diﬀerent. Thus, the role of iNOS polymorphisms
may vary with endemic regions across the globe as does the manifes-
tation of malaria. Due to the confounding evidences [34–36] on NOS
polymorphisms, particularly iNOS, and its functional importance, a
number of studies have been carried out to investigate the role of these
polymorphisms in disease susceptibility and protection, particularly in
malaria and other infectious diseases. Although iNOS is an important
gene involved in the regulation of gene expression, secretion of NO and
host defence mechanism against various infectious and parasitic or-
ganisms, a systematic study of common genetic variations in this gene,
its association with malaria pathology and impact on nitric oxide con-
tent has not been reported from malaria endemic population of
Jharkhand, India. Thus, our objective of the investigation was to ana-
lyze the diﬀerential content of nitric oxide, other associated biochem-
ical markers in order to evaluate the role and plausible association
between iNOS-954G/C and −1173C/T transition polymorphisms and
risk of malaria in the investigated population. Additionally, the other
objective was to understand the translational impact of these poly-
morphisms on the expression of iNOS/NO pathway and components of
oxidative metabolism on patient's actual responses upon plasmodium
infection. In this study, we investigated whether these polymorphisms
in the promoter region of the iNOS gene are inﬂuencing the risk of
plasmodium infection, associated with circulating level of nitric oxide,
and either corroborating antioxidant and ROS content or modulating
the expression of iNOS/NO level in a species speciﬁc infection as
compared to healthy subjects. Among the ﬁndings of these studies
provides prominent insights that transition polymorphisms in iNOS
promoter showed association of genetic susceptibility to the risk of
malaria and critically regulate the expression of iNOS/NO level in
species speciﬁc infection of plasmodium, in addition to promising ra-
tionale for diagnostic potential in human malaria. However, there has
been no published study evaluating the orchestration among the bio-
chemical components, impact of plasmodium infection and poly-
morphic regulation of iNOS expression in clinical isolates from malaria
endemic zone of India.
2. Material and methods
2.1. Study sites and population
A prospective, cross-sectional investigation was conducted in the
general OPD of Sadar hospital in Hazaribag; a tribal prevalent area
representing endemic with stable transmission of malaria district of
Jharkhand, India. The detailed description about the importance of
study site, potential necessity of investigation, overview and socio-de-
mographic status of the investigated population has been described
elsewhere by Sohail et al. [37].
2.2. Patients and demographic information
A total of 320 malaria patients and 210 healthy persons (those
without any evidence of parasites on microscopic examination) of ei-
ther sex, who attended to the local Malaria Counter at Sadar Hospital,
Hazaribag, Jharkhand and were referred by general physicians of the
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hospital and other parts of the districts between August 2012 to
December 2014, were included in this study. Inclusion and classiﬁca-
tion of each case were based on the symptoms, physical signs and la-
boratory ﬁndings of malaria at the onset of disease. On the basis of the
clinical investigation, parasite slide examination and measurement of
axillary body temperature at attendance, patients were deﬁned by (i)
fever (axillary temperature≥37.5 0F, or history of fever in the previous
24 h) with or without other symptoms of malaria (headache, body
aches and malaise), (ii) the presence of any asexual P. falciparum den-
sity, (iii) no symptoms or signs of severe malaria or/and cerebral ma-
laria, and (iv) no other etiology of fever discernible on clinical ex-
amination. Stringent diagnostic criteria were used to diagnose malaria
infection with our trained technical staﬀ. The healthy group included
210 adult relatives and attendants of the patients from same geo-
graphical area and similar ethnicity having no history of malaria in the
last two years. Data collected included basic demographic information,
pattern and onset of infection and use of medications. The subject
characteristics and clinical data are presented in Table 1.
2.3. Sample collection and clinical investigation of infected subject
Peripheral venous blood (3–5 ml) was collected from all the patients
before administration of anti-malarial therapy, aseptically by dripping
from the syringe into a sterile pro-clot activator coated tubes for as-
sessment of serum nitric oxide and in anticoagulant (EDTA) coated tube
for DNA isolation. Blood was allowed to coagulate in a refrigerator for
4–6 h at 4 °C before being processed by centrifugation. Sera were pre-
served in three to ﬁve aliquots immediately stored at −20 °C, and
maintained at −80 °C until measurements were performed. Blood
specimens were collected of all age groups during diﬀerent transmission
periods of the year from positive cases of malaria, who had undergone
clinical investigation and conﬁrmed on the basis of clinical symptoms.
P. vivax or P. falciparum infection was conﬁrmed by thick and thin-
smear blood ﬁlms using standard JSB staining techniques and light
microscopy [38]. All the included patients were found to be infected
with either P. vivax or P. falciparum but not both. However, commercial
(RDT kit) First Response Malaria pLDH/HR2 combo test kits (Premier
Medical Corporation, Mumbai, India) were also used as per the man-
ufacturer's guideline and PCR was used as a screening and veriﬁcation
tool for diagnosing malaria in addition to microscopy.
2.4. Measurement of nitric oxide content
Serum samples were thawed at room temperature and centrifuged
at 14,000 rpm for 10 min at 4 °C before processing of samples for de-
proteination required for nitric oxide estimation. Brieﬂy, deproteina-
tion was carried out by mixing 150 µl of serum with 8 µl of ZnSO4.
Subsequently, 8 µl of NaOH was added, vortexed and centrifuged at
14,000 rpm for 10 min at 4 °C. 100 µl of clear supernatant was used for
estimating the nitric oxide. Circulating levels of nitric oxide were
quantiﬁed in duplicate by a colorimetric method with a linear detection
range of 0.6–200 µM using a QuantiChrom™ Nitric Oxide Assay Kit
(Bioassay Systems, Hayward, CA) according to manufacturer's
instructions and optical densities measured using a microplate reader
set to 540 nm wavelength. The arithmetic mean of the duplicate sam-
ples was considered for analysis.
2.5. Measurement of total antioxidant capacity (TAC) and reactive oxygen
species (ROS)
Total Antioxidant Capacity (TAC) were quantiﬁed by a colorimetric
method with a linear detection range of 1.5–1000 µM using a
QuantiChrom™ Antioxidant Assay Kit (Bioassay Systems, Hayward, CA)
according to manufacturer's instructions and optical densities measured
using a microplate reader set to 570 nm wavelength. Brieﬂy, in this
method Cu2+ is reduced by antioxidant to Cu+ and resulting Cu+
speciﬁcally forms a coloured complex with a dye reagent. The colour
intensity at 570 nm is proportional to TAC in the sample.
Intracellular ROS levels were measured in malaria infected (P. fal-
ciparum and P. vivax) and healthy subject's cells. PBMC were cultured
for 24 h and then harvested, re-suspended in phosphate buﬀered saline
(PBS) and the cell number was counted in a neubauer chamber. Further
cells were incubated with H2DCFDA (20 µM) for 30 min at 37 °C.
Fluorescence was measured spectroﬂuorometrically at 530 nm using an
excitation wavelength of 507 nm. For all measurements, basal ﬂuores-
cence was subtracted.
2.6. Genotyping of iNOS-954G/C and iNOS-1173C/T transition
polymorphism
The iNOS-954G→C polymorphism was determined using the PCR-
RFLP method, whereas the iNOS-1173 C→T polymorphism was de-
termined using mutation speciﬁc (MS)-PCR. PCR was used to amplify
the fragments that contained the selected iNOS polymorphic sites as
described by Levesque et al. [34] and Kun et al. [20,34], respectively.
DNA was extracted from blood spots dried on ﬁlter paper using a DNA
isolation kit (QIAmp Blood Kit: Qiagen, Krefeld, Germany) according to
the manufacturer's instructions. The iNOS-954G→C polymorphism was
determined using the PCR-RFLP method, whereas the iNOS-1173 C→T
polymorphism was determined using mutation speciﬁc (MS)-PCR. PCR
was used to amplify the fragments that contained the selected iNOS
polymorphic sites. The primers of iNOS-954G→C were as follows: 5’-
CATATGTATGGGAATACTGTATTTCAG-3’ (forward) and 5’- TCTGAAC
TAGTCACTTGAGG-3’ (reverse), as previously reported by Levesque
et al. [34]. The primers of iNOS-1173 C→T were as follows: 5’-GACA
AGAAGGAAATGAGTGGACACAGGTAGCAAAGTGTTGAGAC-3’(MS-
P2F),5’-GCATTTTTCCATCATAAAAGTAA-3’(MS-P3R) and5’- GTGGTA
GCAAATGTTGGAAT-3’(MS-P4F), as previously reported by Kun et al.
[20]. In order to detect the variants of −954G/C and −1173C/T of
iNOS promoter, the isolated DNA (100 ng) were ampliﬁed as described
previously [20,34].
2.7. Isolation of peripheral blood mononuclear cells (PBMCs)
Peripheral blood mononuclear cells (PBMCs) were isolated from
both malaria infected and healthy subjects by diluting blood with PBS
Table 1
Demographic and clinical characteristics of the malarial patients and healthy subjects.
Parameters Malaria Patients Mean± SE Healthy Subjects Mean± SE P
Number of Male/Female 157/163 104/106
Age (Year) 26.7±1.03 32.9±1.38 0.0006
Temperature (°F) 100.1± 0.37 98.2±0.05 0.0001
Weight (Kg.) 42.6±0.99 57.6±1.37 0.0001
Height (Feet) 5.0± 0.04 5.2± 0.03 0.0006
BMI (Kg/m2) 18.1±0.36 22.4±0.4 0.0001
Systolic (mmHg) 113±1.58 119±1.91 0.001
Diastolic (mmHg) 74±1.1 73±1.42 NS
A. Kumar et al. Redox Biology 15 (2018) 192–206
194
on Ficoll-Paque Plus (GE Healthcare Life Sciences, India) and cen-
trifuged at 400g for 30 min at room temperature following manufac-
turer's standard guideline. PBMCs were carefully aspirated from Ficoll-
Plasma interface and washed twice with PBS at 300g at 4 °C and re-
suspended in RPMI 1640 and acclimatized for overnight growth in
culture. Further, before subsequent use in RNA isolation and immuno-
blotting, cells were assessed by trypan blue exclusion test and over 90%
viability was observed.
2.8. Evaluation of NOS protein in malaria patients by Western blot analysis
For evaluating the induction of iNOS protein expression from P.
vivax, P. falciparum and healthy subjects; PBMCs were thoroughly wa-
shed twice with ice-cold PBS and resuspended in ice cold RIPA buﬀer
for lysis with 1% Triton X100% and 0.1% SDS following the methods as
previously described [11] and visualised by the procedure of staining
using Colloidal Coomassie Blue G-250. Protein concentration was de-
termined using a protein assay kit (Bio-Rad, Hercules, CA, USA). Equal
amounts of proteins (30 micrograms) were separated by SDS-PAGE,
transferred to PVDF membrane sheets (Millipore, Billerica, MA, USA)
and probed with the anti-iNOS (BD Biosciences; rabbit polyclonal, di-
luted 1:1000) and HRP-conjugated anti-mouse for iNOS secondary an-
tibody (at 1:2000 in 1% skimmed milk TBST), and detection was done
by enhanced chemiluminescence (ECL; Amersham Biosciences, Piscat-
away, NJ) Western blotting detection reagents to visualize im-
munoreactive bands. Immunoreactive bands were digitally scanned and
analyzed with NIH ImageJ for quantiﬁcation by densitometry as protein
expression relative to that of healthy subjects. The human β-actin gene
was used for normalizing the iNOS expression and data represent the
Mean± SE of two independent experiments, and the statistical sig-
niﬁcance was calculated using Student's t-test (N = 7 for each bar re-
presented).
2.9. RNA Isolation and Real Time-PCR
Total RNA was isolated from PBMC of plasmodium (P.vivax and
P.falciparum) infected and healthy subjects using TRI reagents (Ambion,
Austin, TX, USA) following manufacturer's guideline and RT-PCR was
used to determine the induction of iNOS expression. cDNA was syn-
thesized using an iScript cDNA kit (Bio-Rad) following the manufac-
turer's protocol. RT-PCR was performed in the IQ5 thermal cycler (Bio-
Rad) using the iQ SYBR Green I Supermix (Bio-Rad). The PCR program
and primers for iNOS and β-actin were used as previously reported
[39,40]. Each reaction contained 10 µl IQ SYBR Green Supermix re-
agent (Bio-Rad), 10 ng cDNA, and 300 nM each gene-speciﬁc primer in
a ﬁnal volume of 20 µl. All RT-PCRs were performed in duplicate. Data
were analyzed using the ΔΔCT method with β-actin used as normalizer.
2.10. Ethics statement and subject consent
All human blood samples used in this study were collected after
obtaining written informed consent from all study participants under
protocol activities approved by the Institutional Ethics Committee (IEC)
of the Vinoba Bhave University, Hazaribag, Jharkhand and human
ethical guidelines as reﬂected in the guidelines of the Medical Ethics
Committee, Ministry of Health, Govt. of India. The participant clinical
details and individual demographic information were recorded by our
technician in the hospital register as well as in the data register; those
who consented to participate in our study and give blood sample for
further investigation in addition to malaria blood slide examination.
The protocol was approved from IEC, VBU having memo no. VBU/R/
885/2012 dated 05-06-2012. The clinical study and experimental
procedures were well in accordance with the relevant guidelines and
also very much in compliance with the journal's policy.
2.11. Statistical analysis
Data were entered in MS-Excel and analysis were performed using
SPSS v.16 (SPSS Inc., Chicago, IL, USA) and Graphpad Prism version 5.0
(GraphPad Software, Inc., CA, USA). For comparisons of means be-
tween two groups of subjects, the student's t-test were used for normally
distributed data and when data were not normally distributed, non-
parametric tests (Mann-Whitney U) were used to analyze the data. The
biochemical data are expressed as Mean± SE. The mean of the para-
meters for malaria patients and healthy subjects were compared by
using Student's t-test. Data analysis was performed nonparametrically.
The diﬀerences were considered signiﬁcant when p<0.05.
2.12. Calculation of genetic association strength
The model used for risk assessment was the logistic regression ad-
justed for gender and age. Odd ratios (ORs) and 95% Conﬁdence
Intervals (CI) for malarial isolates of each genotype were calculated
with logistic regression to quantitatively assess the degree of associa-
tion and were used to compare categorical variables. Haplotypes fre-
quencies and the extent of association, i.e. the Lewontin's coeﬃcient
(D’) and squared correlation coeﬃcient (r2) for pair wise linkage dis-
equilibrium (LD) of the −954G/C and −1173C/T polymorphism were
calculated by SNP Alyze software (Version 3.1; Dynacom, Mobara-shi,
Japan). The diﬀerences observed between the genotype and allele fre-
quency when compared with healthy subjects and the risk factors for
either P. falciparum or P. vivax were evaluated by univariate analysis
and then adjusted for signiﬁcant predictors in multivariate analysis. All
tests were conducted at the P< 0.05 level of signiﬁcance.
Table 2
Nitric oxide concentration during malaria infection and eﬀect of axillary temperature on nitric oxide content as compared to healthy subjects.
Parameters P. vivax Mean±SE (Range) P Healthy Subjects Mean±SE (Range) P P. falciparum Mean± SE (Range)
Sample Size (N) 210 210 110
Nitric Oxide (µM) 33.5±1.1 0.0001 21.4± 1.1 0.0001 34.2± 1.1
(10.3–83) (1.4–68.9) (12–78.3)
Stratiﬁed Axillary (Body) Temperature at the time of Sampling
(°F) < 99 Mean± SE (Range) P >99–100 Mean±SE (Range) P >100–103 Mean±SE (Range) P Healthy Subjects Mean± SE (Range)
Sample Size 120 117 83 110
Nitric Oxide
(µM)
36.4±2.1 0.0001 34.6± 1.9 0.0006 35.8± 2.6 0.0007 22.5±1.8
(10.9–83) (10.3–71.5) (12–74.8) (5.6–65.4)
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3. Results
3.1. Nitric oxide content in stratiﬁed group of malarial patients and healthy
sera samples
A total of 530 subjects (210 P.vivax infected, 110 P. falciparum in-
fected and 210 healthy subjects) were included in the biochemical
study group and considered for analysis. Table 2 shows the serum nitric
oxide proﬁles of subjects with malarial infection. We observed elevated
nitric oxide content in overall malaria infected subjects as compared to
healthy subjects as shown in Fig. 1A, whereas, marginally higher con-
centration of nitric oxide was observed in P. falciparum infection re-
lative to P. vivax infection; the diﬀerences in concentration were sig-
niﬁcant as compared to healthy subjects, as shown in Table 2. We also
analyzed the gender speciﬁc concentration of nitric oxide in malarial
subjects, as shown in Fig. 1B. Although, the level of nitric oxide were
higher in both the genders (male and female) as compared to healthy
subjects and diﬀerences in concentration were signiﬁcant, surprisingly,
we observed almost similar concentration of nitric oxide between the
genders in both infected and healthy subjects. Further, in view of a
prominent and potent sign & symptom based diagnostic marker and
exclusive prevalence of P. vivax in the investigated region, we evaluated
the impact of stratiﬁed axillary (body) temperature on nitric oxide
concentration, as shown in Fig. 1C. We observed higher concentration
of nitric oxide in all the three stratiﬁed groups of patients based on body
temperature as compared to healthy subject's body temperature and
diﬀerences in concentration were signiﬁcant, as shown in Table 2. In-
terestingly, we found marginally lower concentration of nitric oxide in
99–100°F axillary temperature group as compared to other groups (99
and 100–103°F) and diﬀerences in the content were signiﬁcant. Fur-
ther, we also evaluated the haemoglobin concentration based on stra-
tiﬁed axillary temperature and observed higher haemoglobin level in
higher body temperature range group (101–104°F) of subjects as com-
pared to non-fever and nominal fever (98–99°F) range group of sub-
jects. However, the diﬀerences in axillary temperature were non-sig-
niﬁcant, as shown in Fig. 1D.
3.2. Total antioxidant capacity and reactive oxygen species content in sera
samples and PBMC of malarial patients and healthy subjects
Both, total antioxidant capacity (TAC) and reactive oxygen species
(ROS) are interdependent components of the cascade regulating the
redox metabolism of normal physiology of human system and have
potentially dicotomic implications in several diseases including ma-
larial pathology and protection. Considering the indispensable sig-
niﬁcance and correlation with nitric oxide content and genetic poly-
morphism in our investigated population, we evaluated the TAC and
ROS content in P. falciparum and P. vivax infected subjects. We observed
mean lower total antioxidant content in P.vivax (149.1 mM) and P.
falciparum (133.2 mM) as compared to healthy subjects (437.3 mM).
However, higher TAC content was found in P. vivax compared to P.
falciparum infection as shown in Fig. 2A. Similarly, we found mean
lower ROS content in P. falciparum (166 RFU) and P.vivax (220 RFU)
infection as compared with healthy subjects (313.7 RFU) as shown in
Fig. 2C. However, higher ROS content was observed in vivax infection
as compared with falciparum infection.
We also evaluated mutation speciﬁc antioxidant capacity and ROS
content at both iNOS-954GC/CC and iNOS-1173CT/TT positions in P.
Fig. 1. Circulating concentration of nitric oxide in (A) P. vivax and P. falciparum infected subjects as compared to healthy subjects (B) Plasmodium infected male and female as compared to
healthy counterpart (C) Axillary temperature based stratiﬁed group of plasmodium infected subjects as compared to healthy group. (D) Level of Haemoglobin in axillary temperature
based stratiﬁed plasmodium infected subjects. Data is presented as mean and error bar represent the plus or minus SE *p ≤ 0.01; **p≤ 0.001; ***p ≤ 0.0001 compared with healthy
subjects by one-way analysis using Dunn's multiple comparison test and unpaired ‘t’ test with Welch correlation through Graphpad Prism version 5.0.
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falciparum and P. vivax as compared with mutant genotypes of healthy
subjects and found signiﬁcantly lower antioxidant content in plasmo-
dium infection as shown in Fig. 2B as well as signiﬁcantly lower reactive
oxygen species content in plasmodium infection as shown in Fig. 2D.
However, higher TAC and ROS content was observed in vivax infection
compared to falciparum at both iNOS-954G/C and iNOS-1173C/T
mutation.
3.3. Polymorphism at the iNOS-954G/C and iNOS-1173C/T and
distribution of iNOS −954G/C and −1173C/T genotype in malarial
patients
The ampliﬁed PCR product for the iNOS-954G→C polymorphism
was 573 base pairs. The iNOS-954 polymorphism was screened by the
Restriction Fragment Length Polymorphism using 1.5 U of Bsa1 (New
England Bio Labs, Cambridge, UK) restriction endonucleases in 10 µl of
the PCR product in a total reaction volume of 20 µl and the restricted
PCR fragments were separated on a 3% agarose gel. The gel demon-
strated two fragments of 437 and 136 base pair for the homowild (GG)
genotype, one fragment of 573 base pair for the homomutant (CC)
genotype and three fragments of 573, 437, 136 base pairs for the het-
eromutant (GC) genotype. The ampliﬁed PCR products of the iNOS-
1173C and iNOS-1173 T alleles were of 131 and 102 base pairs, re-
spectively. The genotype distributions for iNOS promoter poly-
morphism at position −954G/C and −1173C/T in vivax and falci-
parum-infected patients were compared with healthy subjects and
detailed results are shown in Table 3. At iNOS-954 position, the C allele
was observed in 23.1% and 16.5% of vivax and falciparum subjects,
respectively as compared to 8.6% in healthy subjects. Similarly, at
iNOS-1173 position the prevalence of T allele was 23.5% and 25.3% in
vivax and falciparum subjects, respectively as compared to 12.3% in
healthy subjects.
3.4. Association between iNOS genotypes and risk of malaria
Using the iNOS −954 GG and iNOS −1173CC as the reference
group, we observed that a statistically signiﬁcant increased risk of
malaria was associated with the−954 and−1173combined (GC+CC)
and (CT+TT) genotypes in both P. vivax and P. falciparum, as shown in
Table 3. However, highest risk was observed to be associated with iNOS
−954 homozygous variant CC (adjusted OR = 2.54; 95% CI =
0.72–2.63), followed by combined (GC+CC) variant (adjusted OR =
1.92; CI = 0.71–1.98) and heterozygous variant GC (adjusted OR =
1.73; CI = 0.25–1.82) in P. vivax followed by P. falciparum CC (adjusted
OR = 1.74; 95% CI = 0.93–1.76), followed by combined (GC+CC)
variant (adjusted OR = 1.68; CI = 0.84–2.25) and heterozygous var-
iant GC (adjusted OR = 1.46; CI = 0.23–1.26). Similarly, highest risk
was observed to be associated with iNOS −1173 homozygous variant
TT (adjusted OR = 1.94; 95% CI = 0.22–1.98), followed by combined
(CT+TT) variant (adjusted OR=1.72; CI=0.71–1.98) and hetero-
zygous variant CT (adjusted OR = 1.63; CI = 0.25–1.82) in P. vivax
followed by P. falciparum; TT (adjusted OR = 1.63; 95% CI =
0.93–1.76), combined (CT+TT) variant (adjusted OR = 1.75; CI =
0.84–2.25) and heterozygous variant CT (adjusted OR = 1.57; CI =
1.23–2.96), shown in Table 3.
Fig. 2. (A) Circulating concentration of total antioxidant capacity (TAC) content in P. falciparum (PF), P. vivax (PV) infected and in healthy subjects (HS). (B) Polymorphisms speciﬁc level
of TAC content in mutant genotypes of malaria infected and in healthy subjects. (C) Circulating concentration of reactive oxygen species (ROS) content in P. falciparum (PF), P. vivax (PV)
infected and in healthy subjects (HS). (D) Polymorphisms speciﬁc level of ROS content in mutant genotypes of malaria infected and in healthy subjects. Data is presented as mean and
error bar represent the plus or minus SE *p≤ 0.01; **p≤ 0.001; ***p≤ 0.0001 compared with healthy subjects by two-way analysis using Dunn's multiple comparison test and paired ‘t’
test through Graphpad Prism version 5.0.
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3.5. Association between serum nitric oxide concentration and iNOS
polymorphism in malaria
Furthermore, to explore the relationship between the iNOS-954 and
iNOS-1173 transition polymorphism and the serum NO activity in in-
fection speciﬁc patients i.e. in vivax and falciparum, we evaluated serum
NO activity in diﬀerent genotype of iNOS-954 and iNOS-1173 as shown
in Table 4. We observed that iNOS-954 genotypes (GG, GC and CC)
group has signiﬁcantly higher serum NO activity in case of vivax
(Fig. 3A), falciparum (Fig. 3B) and overall plasmodium (Fig. 3C) infec-
tion. In P.vivax, we observed increased nitric oxide content in all the
genotypes and the diﬀerences in the nitric oxide content were found to
be statistically signiﬁcant (P = 0.0001, P = 0.01 and P = 0.04 for GG,
GC and CC, respectively). Most interestingly, the risk associated geno-
type i.e. CC show signiﬁcantly highest nitric oxide concentration
(63.77 µmole) as compared to all the genotypes in patients. Similarly,
in case of falciparum infection, we found signiﬁcantly elevated nitric
oxide in GG and CC (P = 0.0001 and P = 0.03, respectively) genotype
as compared to healthy subjects whereas, the NO content was almost
similar in case of GC genotype, shown in Fig. 3B. As expected, the NO
content in the risk associated genotype (CC) in falciparum infection was
found to be highest (65.29 µmole) as compared to all the genotypes in
vivax as well as falciparum subjects, shown in Fig. 3A & B and Table 4. In
addition, we analyzed the eﬀect of iNOS-954 transition polymorphism
on NO content during overall plasmodium infection and interestingly
observed that all the genotypes had signiﬁcantly higher (P = 0.0001, P
= 0.01, and P = 0.03 for GG, GC, and CC genotypes, respectively)
nitric oxide level as compared with healthy subjects as shown in
Fig. 3C. When eﬀects of this polymorphism on NO content were com-
pared between the vivax and falciparum infection, we observed sig-
niﬁcant association between all the genotypes, however, NO content
was higher in GG and GC genotype in vivax as compared to falciparum
whereas NO content was higher in falciparum CC genotype as compared
with vivax infection as shown in Fig. 3D.
In regard to iNOS-1173 transition polymorphism, our observations
showed that compared with healthy subjects, the iNOS-1173 genotypes
Table 3
Genotypic frequencies of the iNOS polymorphism in cases and controls and their associations with risk of Plasmodium vivax and Plasmodium falciparum.
Genotypes Cases Controls Adjusted OR (95% CI) P
iNOS – 954 (P. vivax) N = 119 % N = 110 %
GG 78 65.54 95 86.36 1.00 0.006
GC 27 22.68 11 10 1.73 (0.25–1.82)
CC 14 11.76 4 3.63 2.54 (0.72–2.63)
GC+CC 41 34.44 15 13.63 1.92 (0.71–1.98) 0.027
C allele 23.11 8.63 0.043
iNOS- 954 (P. falciparum) N = 91 % N = 110 %
GG 68 74.72 95 86.36 1.00 0.007
GC 16 17.58 11 10 1.46 (0.23–1.26)
CC 7 7.69 4 3.63 1.74 (0.93–1.76)
GC+CC 23 25.27 15 13.63 1.68 (0.84–2.25) 0.034
C allele 16.48 8.63 0.026
iNOS – 1173 (P. vivax) N = 119 % N = 110 %
CC 72 60.5 81 82.72 1.00 0.036
CT 34 28.57 21 10 1.63 (0.25–1.82)
TT 13 9.24 8 7.27 1.94 (0.22–1.98)
CT+TT 47 37.81 29 17.27 1.72 (0.71–1.98) 0.027
T allele 23.52 12.27 0.043
iNOS- 1173 (P. falciparum) N = 91 % N = 110 %
CC 54 59.34 81 82.72 1.00 0.004
CT 28 30.76 21 10 1.57 (1.23–2.96)
TT 9 9.89 8 7.27 1.63 (0.93–1.76)
CT+TT 37 17.1 29 17.27 1.75 (0.84–2.25) 0.023
T allele 25.27 12.27 0.026
Table 4
Association of iNOS −954G/C and iNOS −1173C/T polymorphism with nitric oxide level in malarial patients as compared to healthy subjects.
Genotype(−954 G/C) GG Pa GC Pa CC Pa
P. vivax N = 76 N = 24 N = 25
Nitric Oxide (µmole) 22.15±0.81 0.0001 47.13± 1.70 0.01 63.77± 2.02 0.04
Healthy Subjects N = 85 N = 18 N = 7
Nitric Oxide (µmole) 11.26±0.56 41.28± 1.67 57.14± 2.83
P. falciparum N = 55 N = 22 N = 14
Nitric Oxide (µmole) 19.44±0.63 0.0001 40.98± 1.29 NS 65.29± 2.07 0.03
Plasmodium Infection N = 125 N = 46 N = 39
Nitric Oxide (µmole) 20.96±0.81 0.0001 44.19± 1.16 0.01 64.32± 1.48 0.03
Genotype (−1173C/T) CC Pa CT Pa TT Pa
P. vivax N = 82 N = 26 N = 11
Nitric Oxide (µmole) 24.73±0.63 0.0001 40.88± 0.89 0.009 56.32± 1.44 NS
Healthy Subjects N = 91 N = 11 N = 8
Nitric Oxide (µmole) 20.05±0.4 32.99± 0.82 52.44± 1.25
P. falciparum N = 58 N = 25 N = 8
Nitric Oxide (µmole) 27.28± 0.48 0.0001 48.13± 1.01 0.0001 65.75± 1.08 0.0001
Plasmodium Infection N = 140 N = 51 N = 19
Nitric Oxide (µmole) 26.01±0.44 0.0001 44.43± 0.83 0.0001 60.29± 1.43 0.003
a When compared with healthy subjects.
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(CC, and CT group) had signiﬁcantly higher serum NO activity (as
shown in Fig. 4A) in case of vivax infection (P = 0.0001, and P = 0.009
for CC, and CT, respectively) and interestingly the risk associated
genotype i.e. TT showed highest nitric oxide activity (56.32 µmole) as
compared to CC and CT genotypes in patients and even more than the
risk associated genotype of the healthy subjects (52.44 µmole) but the
diﬀerence was found to be non-signiﬁcant. However, in case of falci-
parum infection, we found signiﬁcantly elevated nitric oxide in all the
genotypes (P = 0.0001, P = 0.0001, and P = 0.0001 for CC, CT, and
TT respectively) as compared with healthy subjects as shown in Fig. 4B.
In addition to this, we evaluated the eﬀect of iNOS-1173 transition
polymorphism on NO content during overall plasmodium infection and
interestingly observed that all the genotypes had signiﬁcantly higher (P
= 0.0001, P = 0.0001, and P = 0.003 for CC, CT, and TT genotypes,
respectively) nitric oxide level compared with healthy subjects as
shown in Fig. 4C. When the eﬀect of polymorphisms on NO content was
compared between the vivax and falciparum infection, we observed
signiﬁcant association between all the genotypes, although NO content
was higher in falciparum infection as compared to vivax infection in all
the genotypes as shown in Fig. 4D.
3.6. Association between iNOS haplotypes and risk of malaria
The Linkage Disequilibrium tests (LD) showed that the two poly-
morphisms of iNOS at position-954G/C and −1173C/T were in highly
signiﬁcant LD (D’ = 0.6648, r2 = 0.4003, p<0.0001) in the in-
vestigated subjects. Since, −954G/C and −1173C/T polymorphisms
were found to be in highly signiﬁcant LD; hence case-control haplotypes
analysis was performed. Maximum likelihood procedure suggested that
all the possible haplotypes, such as 954G:1173C, 954C:1173T,
954C:1031C and 954G:1173T, respectively, in both the polymorphisms
signiﬁcantly diﬀered between patients and healthy subjects (p = 0.01,
p = 0.001, p = 0.002, p = 0.001, respectively). However, the dom-
inance of 954G:1173C alleles associated haplotypes was observed in
patients (0.7426) compared to healthy subjects (0.3422). It is inter-
esting to report that the distribution of novel 954C:1173T alleles as-
sociated haplotypes were signiﬁcantly higher in case of healthy subjects
(0.4561) as compared to patient group (0.3371). The other two hap-
lotypes (954C:1173C and 954G:1173T, respectively) were also sig-
niﬁcantly diﬀerent but under-represented in the patients (0.061, 0.036,
respectively) as compared to healthy subjects (0.171, 0.138, respec-
tively).
Fig. 3. (A) Eﬀect on nitric oxide level in P. vivax (PV) as compared with healthy subjects (HS) based on iNOS-954G/C polymorphism. (B) Eﬀect on nitric oxide level in P. falciparum (PF) as
compared with healthy subjects (HS) based on iNOS-954G/C polymorphism.(C) Eﬀect on nitric oxide level in plasmodium infection (PI) as compared with healthy subjects (HS) based on
iNOS-954G/C polymorphism. (D) Comparative eﬀect on nitric oxide level in P. vivax (PV) as compared with P. falciparum (PF) based on iNOS-954G/C polymorphism. Data is presented as
mean and error bar represent the plus or minus SE *p≤ 0.01; **p≤ 0.001 and ***p≤ 0.0001 compared with healthy subjects by one-way analysis using Dunn's multiple comparison test
and unpaired ‘t’ test with Welch correlation through Graphpad Prism version 5.0.
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3.7. iNOS expression in the P. vivax and P. falciparum infected subjects
The inducible NOS are actively engaged in defence against various
parasites and parasite induced host factors by inducing nitric oxide,
inﬂicting oxidative damage, regulating gene expression and has been
characterized as potential metabolic component in determining the
course of diseases in a range of infections. In view of the critical role of
the iNOS/NO pathway in pathophysiology and host defence in in-
fectious disease patients including tropical diseases, we investigated
whether plasmodium infection has any inﬂuencing eﬀect on the ex-
pression of iNOS/NO pathway compared to healthy subjects.
Additionally, we also investigated the impact of genetic polymorphism
on the functional expression of iNOS. In order to elucidate the infection
and mutation induced activation mechanisms and biological speciﬁcity
of iNOS/NO pathway; we analyzed the expression of iNOS protein and
RNA from PBMCs of plasmodium infected, healthy and polymorphism
stratiﬁed subjects by employing western blot and qRT-PCR. We re-
solved and blotted the total protein as per the Fig. 5A from plasmodium
infected and healthy subjects and observed higher expression of iNOS
protein in P. Falciparum and P.vivax infected subjects as compared to
healthy subjects, as shown in Fig. 5B. Interestingly, we observed dif-
ferential expression of protein in P. falciparum and P.vivax infected
subjects and diﬀerences were statistically signiﬁcant (P = 0.0004), as
shown in Fig. 5C. Furthermore, western blot analysis revealed almost
2.4 and 1.8 fold increase of iNOS protein in P. vivax and P. falciparum
infected subjects, respectively, as compared to healthy subjects and
diﬀerences were signiﬁcant, as shown in Fig. 5C.
Based on the results so far and precisely, observations of genetic
polymorphisms and diﬀerential protein expression, we conceptualize
that plasmodium speciﬁc infection modulates the iNOS/NO pathway
via perturbed antioxidant and reactive oxygen species components and
they ﬁnely regulate the iNOS/NO expression during malaria pathology.
To further consolidate and substantiate our observation regarding im-
plications of mutation speciﬁc transcriptional induction of iNOS/NO
expression; we analyzed the mRNA expression in both infection and
mutation speciﬁc stratiﬁed samples as compared with healthy subjects.
We observed plasmodium infection speciﬁc increased expression of
iNOS mRNA as compared with healthy subjects, as shown in Fig. 6A.
RT-PCR revealed 2.5 and 1.5 fold increase expression in P. vivax and P.
falciparum infected subjects, respectively, as compared to healthy sub-
jects and diﬀerences were signiﬁcant, as shown in Fig. 6A.
Further, we also evaluated mutation speciﬁc iNOS mRNA expression
in both iNOS-954GC/CC and iNOS-1173CT/TT polymorphism in P.
falciparum and P.vivax as compared with mutant genotypes of healthy
subjects. We observed increased and diﬀerential expression in both
mutations and infections; and diﬀerences were found signiﬁcant, as
shown in Fig. 6B and C, respectively. Though, relatively higher ex-
pression was observed in P.vivax infection as compared to P. falciparum
Fig. 4. (A) Eﬀect on nitric oxide level in P. vivax (PV) as compared with healthy subjects (HS) based on iNOS-1173C/T polymorphism. (B) Eﬀect on nitric oxide level in P. falciparum (PF)
as compared with healthy subjects (HS) based on iNOS-1173C/T polymorphism.(C) Eﬀect on nitric oxide level in plasmodium infection (PI) as compared with healthy subjects (HS) based
on iNOS-1173C/T polymorphism. (D) Comparative eﬀect on nitric oxide level in P. vivax (PV) as compared with P. falciparum (PF) based on iNOS-1173C/T polymorphism. Data is
presented as mean and error bar represent the plus or minus SE *p≤ 0.01; **p≤ 0.001 and ***p≤ 0.0001 compared with healthy subjects by one-way analysis using Dunn's multiple
comparison test and unpaired ‘t’ test with Welch correlation through Graphpad Prism version 5.0.
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infection in both the mutations. Additionally, as observed, anticipated
and point of interest as well that those mutant genotypes (hetero and
homo mutants) in both infection and positions have shown diﬀerential
higher expression of iNOS and overall the diﬀerences were signiﬁcant,
as shown in Fig. 6D.
The above data validate the results of qualitative estimation and
immunoblot, that polymorphism promotes the expression of iNOS in
response to Plasmodium infection. These results collectively suggest that
the presence of both hetero and homo mutant genotype enhances iNOS
expression in response to Plasmodium infection in general and particu-
larly more in case of P. vivax infection, resulting in increased produc-
tion of nitric oxide and critically regulating other orchestrating com-
ponents of the cascades like reactive oxygen and nitrogen intermediates
associated with malarial pathology.
3.8. Association among nitric oxide, axillary temperature (body
temperature) and age in malaria infected subjects
In view of the pathological and physiological relevance of body
temperature during vivax infection, we investigated the prospective
clinical correlation among nitric oxide, axillary temperature and age in
infected subjects with an intention to explore and establish the possi-
bility of biological association. We observed negative and signiﬁcant
association (p = 0.0001 and p = 0.0001) of body temperature with
nitric oxide but weakly correlated (r2 = 0.003 and r2 = 0.04 respec-
tively) both in P. vivax and P. falciparum malarial as compared to
healthy subjects, as shown in Fig. 7B, F, and D, respectively. Interest-
ingly, a tendency towards a marginal decrease in concentration of NO
level with increase in axillary temperature was observed both in plas-
modium infection and healthy subjects; though in falciparum decreasing
concentration of NO level is higher than vivax infection as shown in
Fig. 7.
Further, we observed marginally negative and signiﬁcant associa-
tion (p = 0.0001) of age with nitric oxide but weakly correlated (r2 =
0.04) in vivax infected subjects, although no clear cut trend was ob-
served, as shown in Fig. 7A. In case of falciparum infected subjects,
almost similar observation was found and correlation was also non
signiﬁcant, as shown in Fig. 7E. Conversely, in the case of healthy
subjects, we observed marginally positive and signiﬁcant (p = 0.0001)
association of age with nitric oxide but weakly correlated (r2 = 0.004),
exhibiting a trend of marginal increase in the concentration of nitric
oxide with increase in age, as shown in Fig. 7C.
4. Discussion
Malaria patients show variable degree of clinical manifestations
which appears to be mediated by perturbation in the orchestration of
complex biochemical pathways and immunological cascades of the host
in response to parasites or their toxins. Among the various pathological
mediators, nitric oxide is an important mediator and critical signalling
molecule for malaria which is constitutively expressed by the host
machinery during the complex life cycle of Plasmodium [41]. However,
nitric oxide and related intermediates have dicotomic role in malaria so
far; some reported their involvement in development of disease severity
[13–17], whereas, others have shown protective role [18–23]. Due to
these contradictory observations, this wonder molecule remains enig-
matic for elucidation and intriguing parasitologist to investigate whe-
ther NO is protecting or promoting malarial pathology [42]. In view of
understanding the disease progression and factors inﬂuencing the
clinical outcome of an infection which is crucial for early diagnosis and
prevention strategy; we evaluated the circulating concentration of nitric
oxide, association of transition polymorphism, functional and me-
chanistic impact of transition polymorphism on diﬀerential expression
of nitric oxide synthase in P. vivax and P. falciparum infected subjects.
We observed signiﬁcantly higher nitric oxide in both vivax and falci-
parum infected subjects as compared to healthy subjects, although,
marginally higher NO concentration was observed in vivax infected
subjects as compared to falciparum infection. Our ﬁndings are in ac-
cordance with the observations made by Craig S. Boutlis et al. [35],
Lima-Junior JC et al. [43] and Viktoria Jeney et al. [44]. The changes in
NO levels and iNOS induction in malaria and its involvement in the
clearance of malarial parasites apparently varies according to the stage
of infection, the degree of parasitemia, the strain of Plasmodia and the
target organ or tissue being examined [42]. Additionally, observations
are also inﬂuenced by the coordinated components especially biological
mediators, triggering factors, host innate characteristics, parasites
virulence and localization and the time of sampling [45,46]. Early in-
crease in NO could stimulate Th1 cell types to produce more mediators
(RNI, ROI, O2) to control parasitemia during infection, whereas late
production in liver and spleen appear to have pathological con-
sequences in association with hepatosplenomegaly [47,48]. Malarial
infection has the ability to activate the immune cells which causes the
release of reactive oxygen species (ROS) with the potency of inducing
oxidative damage and cell destruction [49]. In malaria, ROS are gen-
erated as byproduct of parasite haemoglobin metabolism in RBCs,
NADPH oxidase in phagocytes, and through nitric oxide synthase when
the substrate arginine or cofactor tetrahydrobiopterin is lacking [50];
and have dicotomic role ranging from host defense and inﬂuencing
metabolic cascades to disease severity [51]. We observed lower reactive
oxygen species and higher nitric oxide content during plasmodium in-
fection as compared to healthy subjects and this is in accordance with
the observations made by Hemmer et al. [52], Sobolewski et al. [53]
and, recently Lind et al. [54]. Our observation of lower ROS content in
malaria is unconventional and the probable reason which can be at-
tributed to this ﬁnding is that the pathway regulating the cycloox-
ygenase (COX) enzyme complex gets induced through various stimuli
including family of lipid mediators at the site of infection and in-
ﬂammation resulting into the expression of both constitutive COX1 and
inducible COX2 forms of COX [54]. In a paracrine fashion, COX1 and
COX2 interacts with the upregulated iNOS/NO pathway in disease
condition and critically regulate the production of COX2 [55] i.e. ex-
pression of enzyme COX2 is reduced in presence of elevated nitric oxide
Fig. 5. (A) SDS-PAGE proﬁle of total protein for iNOS resolution from Plasmodium-in-
fected isolates compared with healthy subjects. Lane 1, protein marker (M); Lane 2,
homogenate from healthy subjects (HS); lane 3, homogenate from P. falciparum (PF); lane
4, homogenate from P. vivax (PV); (B) Immunoblot of expressed iNOS protein in P. fal-
ciparum and P. vivax as compared with healthy subjects; (C) Analyses of immunoblot as
the mean fold increase relative to the quantity of iNOS induced and normalized to the
level of cellular actin, as assessed by densitometry. The data represent the mean± SE of
two independent experiments (N = 7 for each column) and the statistical signiﬁcance
*P< 0.05; **P< 0.0005 compared with healthy subjects was calculated using two-way
analysis using Tukey's multiple comparison test through GraphPad Prism version 5.0.
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level by concentration dependent feed-back inhibition mechanism via
the c-Ab1/Arg pathway, resulting into decreased ROS production.
Moreover, when NOS activity and NO content are high, O2- production
is suppressed [56,57] as L-Arg regulate NO production by enhancing
ARG1 transcription and the resultant up regulation and/or over-
expression of ARG1 during infection induces negative feed-back loop
mechanism to regulate and suppress its own production via L-Arg pre-
treatment, culminating into reduced ROS production [58] and is the
likely causal mechanism operating in our observation. Furthermore, to
avoid and overcome the oxidative stress and damages and to equilibrate
the redox metabolism; plasmodium utilizes the orchestrated compo-
nents of its antioxidant machinery against the eﬃcient enzymatic host's
antioxidant defense system. In order to understand the alterations in
redox interplay and predisposition of disease severity in clinical per-
spective of the host responses to malaria; we evaluated and observed
decreased total antioxidant content and increased nitric oxide content
in plasmodium infected patients as compared to healthy subjects. Our
observation of lower antioxidant is in agreement with the ﬁnding of
Blair et al. [59], Aghedo et al. [60] and Das et al. [61] who showed its
correlation with disease severity. The reason of this observation can be
attributed to the excess utilization of host's antioxidants to combat the
malaria infection-associated oxidative damages [62]. Degradation of
antioxidant enzymes as well as haemoglobin by malaria parasite to
produce its own protein has been reported [63] and this might be
contributing to the decline in total antioxidant status. The total anti-
oxidant level varied inversely with the severity of malaria indicating
that our investigated subjects may have clinical symptoms alike mild/
moderate malaria [64,65]. Therefore, our study shows that free radical
challenge could induce reduction in antioxidant levels and strengthens
the involvement of antioxidants in the defense against ROS induced
damages by the parasite. Further, antioxidants have shown signiﬁcant
inﬂuence on host's immunity and in neutralizing the adverse eﬀect of
free-radicals and associated toxic byproduct. Antioxidants are degraded
by malarial parasites to derive amino acids and other essential
Fig. 6. Fresh PBMCs were processed from healthy subjects (HS) and P. vivax (PV) and P. falciparum (PF) infected patients for RNA isolation and cDNA. (A) Diﬀerential expression of iNOS
during Plasmodium infection. (B) iNOS-954G/C mutation-speciﬁc expression of iNOS; (C) iNOS-1173C/T mutation-speciﬁc expression of iNOS; and (D) Relative expression of iNOS in
plasmodium species and in mutant genotypes of both transition polymorphisms. Fold induction was calculated using the ΔΔCT method of qRT-PCR, in which uninfected samples were
compared to infected samples relative to β-actin levels as per the cropped gel image placed at the top of the each bar representing. Data are presented as means and error bars
represent± SE from seven isolates. Results are representative of at least three independent experiments. *P< 0.05; **P< 0.0005 compared with healthy subjects by one-way analysis
using Tukey's multiple comparison test through GraphPad Prism version 5.0.
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molecules for survival as the same may not be replenished by red blood
cells due to augmented protein synthesis in diseased condition, and
might be one of the plausible reasons behind overall depleted total
antioxidant content in the host [66,67].
In genetic polymorphism study, we observed that iNOS-954
GG+GC and iNOS-954 CC genotypes were associated with an increased
risk of malaria. The association was more pronounced in patients with
vivax malaria and in overall Plasmodium infection compared to falci-
parum malaria. However, the association was observed to be signiﬁcant
in all the three cases as compared to healthy group. Further, iNOS-
1173CC+CT genotypes and the iNOS-1173 TT genotypes were also
observed to be associated with an increased risk of malaria, but con-
trary to the observation of iNOS-954; the association was more pro-
nounced in patients with falciparum malaria and in overall Plasmodium
infection compared to vivax malaria. This study does not support a
protective association in both type of transition polymorphism; rather it
supports signiﬁcant association with malarial pathology which is in
accordance with the previous observations made by other investigators
in malaria [31,32]. Our ﬁndings further endorses and elucidates the
observation of Hobbs et al. regarding association of transition
polymorphism at −954 and −1173 position of NOS promoter with
malaria disease progression and severity in African population; al-
though genotype distributions and degree of association in both the
transition polymorphism vary with the ethnicity [31]. These ﬁndings in
the investigated population may be potentially limited by the sample
size in addition to various other factors like increased recombination
near SNP sites, gene conversion, selection involving the 5’ and 3’ SNP
clusters, or epistatic selection. Additionally, geographic variation, sus-
ceptibility to malaria and disease phenotype may be attributed to dif-
ferences in host genetics, parasite strains and malaria epidemiology.
The functional signiﬁcance of these conﬂicting observations is ambig-
uous, suggesting that the relationship between NOS2 polymorphism
and malaria severity is much more complex than previously described
[68–70]. Disparities in allele frequency make an ideal source of spur-
ious association; however they should not be always overlooked as
diﬀerences in functional alleles of this sort might explain varied re-
sponse between populations in susceptibility/protection from diseases.
The divergent evolutionary histories per locus underlying such allele
diﬀerence may often be shaped by related infectious diseases that
shares related biological mechanisms; hence explaining major
Fig. 7. Association of nitric oxide, axillary temperature (body temperature) and age during plasmodium infection. (A) Correlation between nitric oxide concentration and age during vivax
infection. (B) Correlation between nitric oxide concentration and body temperature during vivax infection. (C) Correlation between nitric oxide concentration and age in healthy subjects.
(D) Correlation between nitric oxide concentration and body temperature in healthy subjects. (E) Correlation between nitric oxide concentration and age during falciparum infection. (F)
Correlation between nitric oxide concentration and body temperature during falciparum infection. Statistical signiﬁcance was determined by Student's t-test.
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diﬀerences between populations for various disease proﬁles [71].
Therefore, it is clear that comparisons of these parameters between
diﬀerent regions of the genome are highly dependent on factors that
may have little to do with the intrinsic mutation rate or the inﬂuences
of selective pressure on a given region of DNA [70].
Moreover, our ﬁndings are pertinent and their interpretation can be
attributed to several reasons because the iNOS-954 polymorphism is
located in the iNOS promoter region, which could be an activator of
gene expression and nitric oxide production [20]. iNOS-954C allele, but
not the iNOS-954G allele, may have a higher aﬃnity to a DNA binding
protein and thus, translational activity and NOS mRNA levels were
increased in the iNOS-954C allele resulting in overall enhanced NOS
expression. This rationale is quite well in accordance with our ﬁndings
of increased iNOS protein and mRNA level both in infection induced as
well as mutation speciﬁc expression as previously observed by Kun
et al. [20], Ascenzi P et al. [72] and Chiwakata CB et al. [73]. This also
corroborates with our observation that iNOS-954C allele showed in-
creased NO levels. Although, dicotomic and opposing ﬁndings were also
reported by some earlier investigators regarding protective role and
parasite killing depending upon diﬀerent cell types from diﬀerent re-
gions [74], several others opined that transition polymorphisms in
promoter region of iNOS gene alters NO level and a higher NOS activity
in human PBMCs are associated with uncomplicated malaria [31], se-
vere malaria and clinical complications in addition to activating pro-
tective pathways [11,75,76]. NO production and expression of iNOS in
Plasmodium infection is activated by variety of critical triggering com-
ponents in the balancing of arginine-nitric oxide pathway, including
increased arginase activity and cell-free haemoglobin in plasma, low
levels of the NOS substrate arginine and the NOS cofactor tetra-
hydrobiopterin [77] in addition to multiple mechanisms by which NO
bioavailability is critically regulated for impairment of NOS2 expres-
sion. Interestingly, it also facilitates alterations of unique monocyte
activation phenotypes through PBMC/monocytes that plausibly reg-
ulates the eﬀective concentration of nitric oxide, adherence of para-
sitized RBC to endothelium; a potential regulator of pathophysiological
mechanism in malaria disease progression and protection [78,79]. In
view of our observation of elevated nitric oxide concentration, ex-
pression of NOS in uncomplicated malaria subjects and polymorphic
variability in NOS promoter region and to substantiate our ﬁndings of
signiﬁcantly associated observation in disease progression, we would
like to discuss (though contrary to our ﬁndings with a diﬀerentiating
limitations of study design and population) a very prominent and bio-
logically rational observations made by Anstey NM et al. [11] that nitric
oxide production and NOS2 expression are inversely correlated with
disease severity and suppression of NO synthesis increases with disease
severity in Tanzanian children cohort. Further, investigators also
strikingly observed that suppression of NO-mediated protective im-
munity after the infection may result in inadequate control of parasite
replication and contributed to progression of clinical malaria in chil-
dren. This very observation aptly supports our ﬁndings and are me-
chanistically indicative of very relevant observation in adult population
that non-suppression i.e. increased expression of NO synthesis is a likely
contributory factor for both mild or uncomplicated malaria and upre-
gulated activity of NOS. Thus, elucidating the genetic factors provide a
signiﬁcant contribution to the variability observed in malaria; will be
crucial for understanding the genetic epidemiology, malaria pathology
and association studies moving towards a genome–wide era [80]. Re-
gardless of exact functional relevance, existing evidences and based on
our ﬁndings, we hypothesize that the relevant role of transition poly-
morphism iNOS-954G→C and −1173C→T are associated with circu-
lating levels of nitric oxide and increasing the risk of disease suscept-
ibility or progression in malaria infection but do not play signiﬁcant
role in clinical severity. Our results of iNOS polymorphism with NO
level, evaluation of redox components and functional genomics during
plasmodium infection suggest that evaluation of nitric oxide level and
its polymorphism may be considered as a reliable molecular and
biochemical marker, possess promising rational for diagnostic potential
and chemotherapeutic interventions in clinical malaria. Genetic varia-
tion in iNOS promoter region is of biological signiﬁcance and may play
pivotal role in host defense mechanisms against malaria pathology by
enhancing anti-oxidants enzymes and stimulating the infection induced
biochemical cascade against plasmodium pathology. In the present
study, we have applied a comprehensive and systematic genotyping
based case-control research strategy to characterize common genetic
variation in NOS, a gene that encodes a protein that plays diverse roles,
from phase II drug metabolism to the regulation of apoptosis. Knowl-
edge of common iNOS SNPs and haplotypes, as well as understanding of
their functional implications; contribute both to mechanistic and epi-
demiologic studies of the involvement of NO in malarial pathogenesis
as well as individual variation in response to anti-malarial drug
therapy.
5. Conclusion
Irrespective of whether therapies directed against NOS will be
useful in the management of clinical malaria, study of the eﬀects of
selective activation and evaluation of nitric oxide during natural in-
fection will provide unique and valuable insights into the under-
standing of biochemical orchestration and patho-biology of malaria,
since our current understanding of these mechanisms is limited. As the
ﬁndings are novel and well aware of the limited number of subjects,
deserves to be investigated in a large study group. In conclusion, our
data provide link between the clinically acquired diﬀerential bio-
chemical orchestration, infection and polymorphism through complex
interplay of oxidant-antioxidant cascade in population exposed to vivax
and falciparum malaria and could be contributing in the development
of recombinant NO based anti-malarial drug targets. However, the re-
liability of nitric oxide and their polymorphisms, as a sensitive bio-
chemical, genetic and diagnostic marker in clinical usefulness awaits
further well conducted clinical investigations as to permit interventions
in order to control and diagnose malaria infection.
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